Program
tanimilast
Also written as “CHF6001 DPI”, “CHF6001” and “CHF 6001”.
Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Asthma · Bronchitis, Chronic, led by Chiesi Farmaceutici.
Furthest: phase 3, since Nov 16, 202015 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chiesi Farmaceutici | 150 open or running | phase 3since Nov 16, 2020 | Aug 23, 2012 | none ahead |
Also a collaborator on its studies: sgs-s-a and quintiles-inc.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 23, 2012First study: phase 2 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT01730404 · 55 enrolled · Ireland, United Kingdom
- Sep 4, 2012Phase 2 study in AsthmaNCT01689571 · 36 enrolled · United Kingdom
- Jan 22, 2015Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT02386761 · 48 enrolled · United Kingdom
- Oct 28, 2016Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT03004495 · 36 enrolled · United Kingdom
- Nov 24, 2016Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT02986321 · 1,130 enrolled
- Dec 2, 2016Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT03004417 · 61 enrolled · United Kingdom
- Nov 16, 20202 phase 3 studies in Pulmonary Disease, Chronic ObstructiveNCT04636814, NCT04636801
- Jan 29, 2021Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT04739774 · 24 enrolled · Belgium
- Feb 8, 2021Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT04756960 · 8 enrolled · United Kingdom
- May 10, 2022Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT05373953 · 44 enrolled · Bulgaria
- Aug 31, 2023Phase 2 study in AsthmaNCT06029595 · 517 enrolled · Argentina, Bulgaria, Czechia and more
- Apr 29, 2024Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT06395610 · 24 enrolled · Bulgaria
- Mar 5, 2025Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT06892756 · 30 enrolled · Bulgaria
- Mar 10, 2025Phase 2 study in AsthmaNCT06900816 · 50 enrolled · Bulgaria
TargetBeta
“Phosphodiesterase 4 inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Roflumilastrule | AstraZeneca | phase 4 | 61 |
| apremilastrule | Amgen | phase 4 | 48 |
| ensifentrinerule | Merck | phase 3 | 17 |
| difamilastrule | Otsuka | phase 3 | 16 |
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06900816Asthma · Bulgaria | 2 | Completed | Aug 11, 2025 | 50 |
| NCT06892756Pulmonary Disease, Chronic Obstructive · Bulgaria | 1 | Completed | Jun 20, 2025 | 30 |
| NCT06395610Pulmonary Disease, Chronic Obstructive · Bulgaria | 1 | Completed | Jun 18, 2024 | 24 |
| NCT06029595Asthma · Argentina, Bulgaria, Czechia and more | 2 | Terminated | Dec 9, 2025 | 517 |
| NCT05373953Pulmonary Disease, Chronic Obstructive · Bulgaria | 1 | Completed | Nov 25, 2022 | 44 |
| NCT04756960Pulmonary Disease, Chronic Obstructive · United Kingdom | 1 | Completed | Apr 29, 2021 | 8 |
| NCT04739774Pulmonary Disease, Chronic Obstructive · Belgium | 1 | Completed | Apr 20, 2021 | 24 |
| NCT04636814Pulmonary Disease, Chronic Obstructive · United States, Argentina, Austria and more | 3 | Terminated | Dec 23, 2025 | 3,973 |
| NCT04636801Pulmonary Disease, Chronic Obstructive · United States, Albania, Argentina and more | 3 | Terminated | Oct 31, 2025 | 4,710 |
| NCT03004417Pulmonary Disease, Chronic Obstructive · United Kingdom | 2 | Completed | Dec 28, 2017 | 61 |
| NCT02986321Pulmonary Disease, Chronic Obstructive | 2 | Completed | Oct 4, 2017 | 1,130 |
| NCT03004495Pulmonary Disease, Chronic Obstructive · United Kingdom | 1 | Completed | Aug 2016 | 36 |
| NCT02386761Pulmonary Disease, Chronic Obstructive · United Kingdom | 1 | Completed | May 2015 | 48 |
| NCT01689571Asthma · United Kingdom | 2 | Completed | Apr 2013 | 36 |
| NCT01730404Pulmonary Disease, Chronic Obstructive · Ireland, United Kingdom | 2 | Completed | Oct 2013 | 55 |
How it is read
Names in the registry
- “CHF6001 DPI”, 4 entries
- “CHF6001”, 4 entries
- “CHF 6001”, 2 entries
- “CHF6001 1600µg”, 1 entry
- “CHF6001 3200µg”, 1 entry
Conditions, from the studies’ own filings
- Pulmonary Disease, Chronic Obstructive, 10 studies
- Asthma, 3 studies
- Bronchitis, Chronic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.